XML 62 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Revenue recognition - Narrative (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2017
USD ($)
Nov. 30, 2014
USD ($)
Jan. 31, 2014
USD ($)
Nov. 30, 2011
USD ($)
compound
Mar. 31, 2018
USD ($)
segment
deliverable
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
deliverable
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Number of operating segments | segment         1    
Net product revenue         $ 55,981,000 $ 26,442,000  
Contract with customer, liability             $ 11,891,000
Upfront cash payment         1,346,000    
Licensing And Collaboration Agreement              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Upfront cash payment       $ 30,000,000      
Revenue recognition, milestone method, revenue recognized $ 20,000,000 $ 10,000,000 $ 7,500,000        
Revenues         100,000 100,000  
Licensing And Collaboration Agreement | Research And Development Event Milestones              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Revenue recognition, milestone, potential achievements         135,000,000    
Licensing And Collaboration Agreement | Sales Milestones              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Revenue recognition, milestone, potential achievements         325,000,000    
Discovery Agreements              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Revenues         0 0  
Early Stage Collaborations              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Revenues         0 $ 0  
Early Stage Collaborations | Research And Development Event Milestones              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Revenue recognition, milestone, potential achievements         143,000,000    
Early Stage Collaborations | Sales Milestones              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Revenue recognition, milestone, potential achievements         252,000,000    
United States | Emflaza              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Net product revenue         19,200,000    
Non-US | Translarna              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Net product revenue         $ 36,800,000    
Collaborative Arrangement | Roche And Sma Foundation              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Number of compounds in preclinical development | compound       3      
Number of significant deliverables | deliverable             2
Collaboration And Discovery Agreements              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Number of significant deliverables | deliverable         2    
Minimum | Collaboration And Discovery Agreements              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Collaborative arrangements research period for applying discovery technology         3 years    
Maximum | Collaboration And Discovery Agreements              
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]              
Collaborative arrangements research period for applying discovery technology         4 years